Richard Long

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8198998/publications.pdf

Version: 2024-02-01

471509 377865 1,316 67 17 34 citations h-index g-index papers 67 67 67 1384 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	How much do smear-negative patients really contribute to tuberculosis transmissions? Re-examining an old question with new tools. EClinicalMedicine, 2022, 43, 101250.	7.1	16
2	The Radiographic and Mycobacteriologic Correlates of Subclinical Pulmonary TB in Canada. Chest, 2022, 162, 309-320.	0.8	9
3	Chapter 15: Monitoring tuberculosis program performance. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 229-241.	0.5	2
4	Chapter 3: Diagnosis of tuberculosis disease and drug-resistant tuberculosis. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 33-48.	0.5	4
5	Chapter 12: An introductory guide to tuberculosis care to improve cultural competence for health care workers and public health professionals serving Indigenous Peoples of Canada. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 184-193.	0.5	2
6	Chapter 2: Transmission and pathogenesis of tuberculosis. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 22-32.	0.5	2
7	Local Transmission Plays No Important Role in the Occurrence of Multidrug-Resistant Tuberculosis in Immigrants to Canada: An In-depth Epidemiologic Analysis. Journal of Infectious Diseases, 2021, 224, 1029-1038.	4.0	1
8	Individual and public health consequences associated with a missed diagnosis of pulmonary tuberculosis in the emergency department: A retrospective cohort study. PLoS ONE, 2021, 16, e0248493.	2.5	4
9	Effectiveness and cost-effectiveness of a health systems intervention for latent tuberculosis infection management (ACT4): a cluster-randomised trial. Lancet Public Health, The, 2021, 6, e272-e282.	10.0	18
10	Engaging frontline providers: an important key to eliminating tuberculosis in Canada, and other high-income countries. Canadian Journal of Public Health, 2021, 112, 872-876.	2.3	4
11	Treating latent tuberculosis infection (LTBI) with isoniazid and rifapentine (3HP) in an inner-city population with psychosocial barriers to treatment adherence: A qualitative descriptive study. PLOS Global Public Health, 2021, 1, e0000017.	1.6	3
12	Tuberculosis and COVID-19 in Canada. EClinicalMedicine, 2020, 27, 100584.	7.1	3
13	Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials. Clinical Infectious Diseases, 2020, 73, e3545-e3554.	5.8	19
14	Prompt recognition of infectious pulmonary tuberculosis is critical to achieving elimination goals: a retrospective cohort study. BMJ Open Respiratory Research, 2020, 7, e000521.	3.0	11
15	Incidence and significance of venous thromboembolism in critically ill pulmonary tuberculosis patients. European Respiratory Journal, 2020, 56, 2001753.	6.7	1
16	Enhancing the public health impact of latent tuberculosis infection diagnosis and treatment (ACT4): protocol for a cluster randomised trial. BMJ Open, 2019, 9, e025831.	1.9	18
17	ls there a fundamental flaw in Canada's post-arrival immigrant surveillance system for tuberculosis?. PLoS ONE, 2019, 14, e0212706.	2.5	13
18	No evidence of increased risk of acquired rifampin resistance. Cmaj, 2019, 191, E1314-E1315.	2.0	1

#	Article	IF	Citations
19	Would program performance indicators and a nationally coordinated response accelerate the elimination of tuberculosis in Canada?. Canadian Journal of Public Health, 2019, 110, 31-35.	2.3	7
20	Two Row Wampum, Human Rights, and the Elimination of Tuberculosis from High-Incidence Indigenous Communities. Health and Human Rights, 2019, 21, 253-265.	1.3	5
21	Predicting pulmonary tuberculosis in immigrants: a retrospective cohort study. ERJ Open Research, 2018, 4, 00170-2017.	2.6	5
22	Determinants of tuberculosis trends in six Indigenous populations of the USA, Canada, and Greenland from 1960 to 2014: a population-based study. Lancet Public Health, The, 2018, 3, e133-e142.	10.0	25
23	Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. New England Journal of Medicine, 2018, 379, 440-453.	27.0	267
24	Safety and Side Effects of Rifampin versus Isoniazid in Children. New England Journal of Medicine, 2018, 379, 454-463.	27.0	124
25	Prevalence of latent tuberculosis infection in Syrian refugees to Canada. Canadian Journal of Public Health, 2018, 109, 8-14.	2.3	14
26	Towards the elimination of paediatric tuberculosis in high-income, immigrant-receiving countries: a 25-year conventional and molecular epidemiological case study. ERJ Open Research, 2018, 4, 00131-2017.	2.6	9
27	Epidemiological and genomic determinants of tuberculosis outbreaks in First Nations communities in Canada. BMC Medicine, 2018, 16, 128.	5 . 5	17
28	Efficacy of screening and treatment of latent tuberculosis infection. Mathematical Population Studies, 2017, 24, 21-36.	2.2	1
29	Effectiveness of Canada's tuberculosis surveillance strategy in identifying immigrants at risk of developing and transmitting tuberculosis: a population-based retrospective cohort study. Lancet Public Health, The, 2017, 2, e450-e457.	10.0	24
30	Tuberculosis transmission in the Indigenous peoples of the Canadian prairies. PLoS ONE, 2017, 12, e0188189.	2.5	7
31	Contact investigation outcomes of Canadian-born adults with tuberculosis in Indigenous and non-Indigenous populations in Alberta. Canadian Journal of Public Health, 2016, 107, e106-e111.	2.3	6
32	"Years ago― reconciliation and First Nations narratives of tuberculosis in the Canadian Prairie Provinces. Critical Public Health, 2016, 26, 381-393.	2.4	5
33	Chest Radiographic Patterns and the Transmission of Tuberculosis: Implications for Automated Systems. PLoS ONE, 2016, 11, e0154032.	2.5	21
34	Tuberculosis elimination in Canada: Truce or victory?. Cmaj, 2015, 187, 1191-1192.	2.0	3
35	Is Early Tuberculosis Death Associated with Increased Tuberculosis Transmission?. PLoS ONE, 2015, 10, e0117036.	2.5	8
36	Do "Virtual―and "Outpatient―Public Health Tuberculosis Clinics Perform Equally Well? A Program-Wide Evaluation in Alberta, Canada. PLoS ONE, 2015, 10, e0144784.	2.5	21

#	Article	IF	CITATIONS
37	Therapeutic drug monitoring and the conservative management of chronic tuberculous empyema: case report and review of the literature. BMC Infectious Diseases, 2015, 15, 327.	2.9	13
38	A 10-Year Population Based Study of â€~Opt-Out' HIV Testing of Tuberculosis Patients in Alberta, Canada: National Implications. PLoS ONE, 2014, 9, e98993.	2.5	15
39	Increase in Multidrug-resistant Tuberculosis (MDR-TB) in Alberta Among Foreign-born Persons: Implications for Tuberculosis Management. Canadian Journal of Public Health, 2013, 104, e22-e27.	2.3	13
40	Marked Disparity in the Epidemiology of Tuberculosis among Aboriginal Peoples on the Canadian Prairies: the Challenges and Opportunities. Canadian Respiratory Journal, 2013, 20, 223-230.	1.6	21
41	Multidrug and Extensively Drug-resistant Tuberculosis in Canada 1997–2008: Demographic and Disease Characteristics. PLoS ONE, 2013, 8, e53466.	2.5	34
42	A process for the inclusion of Aboriginal People in health research: Lessons from the Determinants of TB Transmission project. Social Science and Medicine, 2011, 72, 733-738.	3.8	31
43	High HIV-TB Co-infection Rates in Marginalized Populations: Evidence from Alberta in Support of Screening TB Patients for HIV. Canadian Journal of Public Health, 2010, 101, 202-204.	2.3	10
44	Sustained Intra- and Inter-jurisdictional Transmission of Tuberculosis within a Mobile, Multi-ethnic Social Network: Lessons for Tuberculosis Elimination. Canadian Journal of Public Health, 2010, 101, 205-209.	2.3	7
45	The Feasibility of Using an â€~Opt-Out' Approach to Achieve Universal HIV Testing of Tuberculosis Patients in Alberta. Canadian Journal of Public Health, 2009, 100, 116-120.	2.3	9
46	Lupus Vulgaris Occurring in a Locus Minoris Resistentiae. Journal of Cutaneous Medicine and Surgery, 2009, 13, 313-316.	1.2	2
47	Empirical Treatment of Communityâ€Acquired Pneumonia and the Development of Fluoroquinoloneâ€Resistant Tuberculosis. Clinical Infectious Diseases, 2009, 48, 1354-1360.	5.8	72
48	Treatment of a Tuberculous Empyema with Simultaneous Oral and Intrapleural Antituberculosis Drugs. Canadian Respiratory Journal, 2008, 15, 241-243.	1.6	13
49	Why internationally adopted children should be screened for tuberculosis. Cmaj, 2007, 177, 172-173.	2.0	6
50	The Canadian Lung Association/Canadian Thoracic Society and Tuberculosis Prevention and Control. Canadian Respiratory Journal, 2007, 14, 427-431.	1.6	9
51	Mycobacterium tuberculosis Infection in First Nations Preschool Children in Alberta. Canadian Journal of Public Health, 2007, 98, 116-120.	2.3	4
52	Pediatric Tuberculosis in Alberta. Canadian Journal of Public Health, 2007, 98, 276-280.	2.3	15
53	Physician experience, public health and the management of tuberculosis. Cmaj, 2006, 175, 759-759.	2.0	3
54	Inhaled Nitric Oxide Treatment of Patients with Pulmonary Tuberculosis Evidenced by Positive Sputum Smears. Antimicrobial Agents and Chemotherapy, 2005, 49, 1209-1212.	3.2	34

#	Article	IF	Citations
55	Bronchial Anthracofibrosis and Tuberculosis: CT Features Before and After Treatment. American Journal of Roentgenology, 2005, 184, S33-S36.	2.2	35
56	Pediatric Tuberculosis in Alberta First Nations (1991–2000). Canadian Journal of Public Health, 2004, 95, 249-255.	2.3	9
57	Relative Versus Absolute Noncontagiousness of Respiratory Tuberculosis on Treatment. Infection Control and Hospital Epidemiology, 2003, 24, 831-838.	1.8	26
58	Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. Cmaj, 2003, 168, 1153-6.	2.0	18
59	Recommendations for screening and prevention of tuberculosis in patients with HIV and for screening for HIV in patients with tuberculosis and their contacts. Cmaj, 2003, 169, 789-91.	2.0	7
60	Tuberculosis Control in Alberta. Canadian Journal of Public Health, 2002, 93, 264-266.	2.3	3
61	Medical versus Surgical Treatment of a Primary Tuberculous Pleural Peel. Canadian Respiratory Journal, 2001, 8, 449-453.	1.6	1
62	Postsanatorium Pattern of Antituberculous Drug Resistance in the Canadian-born Population of Western Canada: Effect of Outpatient Care and Immigration. American Journal of Epidemiology, 2001, 153, 903-911.	3 . 4	9
63	Drug Resistance Study of Mycobacterium tuberculosis in Canada, February 1, 1993 to January 31, 1994. Canadian Journal of Public Health, 2000, 91, 366-370.	2.3	3
64	Multidrug-Resistant Tuberculosis in Alberta and British Columbia, 1989 to 1998. Canadian Respiratory Journal, 1999, 6, 155-160.	1.6	20
65	Transcontinental Spread of Multidrug-resistant <i>Mycobacterium bovis</i> . American Journal of Respiratory and Critical Care Medicine, 1999, 159, 2014-2017.	5 . 6	38
66	The Chest Roentgenogram in Pulmonary Tuberculosis Patients Seropositive for Human Immunodeficiency Virus Type 1. Chest, 1991, 99, 123-127.	0.8	136
67	How Much Do Smear-Negative Patients Really Contribute to Tuberculosis Transmissions? Re-Examining an Old Question with New Tools. SSRN Electronic Journal, 0, , .	0.4	O